You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTolterodine
Accession NumberDB01036  (APRD00146)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
Structure
Thumb
Synonyms
(+)-(R)-2-(alpha-(2-(Diisopropylamino)ethyl)benzyl)-p-cresol
(+)-Tolterodine
Tolterodina
Tolterodine
Tolterodinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Detroltablet, film coated1 mg/1oralPharmacia and Upjohn Company1998-03-25Not applicableUs
Detroltablet1 mgoralPfizer Canada Inc1998-11-26Not applicableCanada
Detroltablet, film coated2 mg/1oralSTAT Rx USA LLC1998-03-25Not applicableUs
Detroltablet, film coated2 mg/1oralPharmacia and Upjohn Company1998-03-25Not applicableUs
Detroltablet2 mgoralPfizer Canada Inc1998-11-23Not applicableCanada
Detrol LAcapsule (extended release)4 mgoralPfizer Canada Inc2002-03-26Not applicableCanada
Detrol LAcapsule, extended release2 mg/1oralPhysicians Total Care, Inc.2004-09-03Not applicableUs
Detrol LAcapsule, extended release4 mg/1oralCardinal Health2000-12-22Not applicableUs
Detrol LAcapsule, extended release4 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-28Not applicableUs
Detrol LAcapsule, extended release2 mg/1oralPharmacia and Upjohn Company2000-02-22Not applicableUs
Detrol LAcapsule, extended release2 mg/1oralCardinal Health2000-12-22Not applicableUs
Detrol LAcapsule (extended release)2 mgoralPfizer Canada Inc2002-03-26Not applicableCanada
Detrol LAcapsule, extended release4 mg/1oralPhysicians Total Care, Inc.2004-09-03Not applicableUs
Detrol LAcapsule, extended release4 mg/1oralPharmacia and Upjohn Company2000-02-22Not applicableUs
Detrol LAcapsule, extended release4 mg/1oralPd Rx Pharmaceuticals, Inc.2000-02-22Not applicableUs
Gd-tolterodinetablet1 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-tolterodinetablet2 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-tolterodine LAcapsule (extended release)2 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-tolterodine LAcapsule (extended release)4 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Mint-tolterodinetablet1 mgoralMint Pharmaceuticals Inc2015-12-16Not applicableCanada
Mint-tolterodinetablet2 mgoralMint Pharmaceuticals Inc2015-12-16Not applicableCanada
Mylan-tolterodine ERcapsule (extended release)4 mgoralMylan Pharmaceuticals Ulc2015-10-23Not applicableCanada
Mylan-tolterodine ERcapsule (extended release)2 mgoralMylan Pharmaceuticals Ulc2015-10-23Not applicableCanada
Ran-tolterodinetablet1 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-tolterodinetablet2 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Sandoz Tolterodine LAcapsule (extended release)4 mgoralSandoz Canada Incorporated2015-12-16Not applicableCanada
Sandoz Tolterodine LAcapsule (extended release)2 mgoralSandoz Canada Incorporated2015-12-16Not applicableCanada
Teva-tolterodinetablet1 mgoralTeva Canada Limited2015-12-16Not applicableCanada
Teva-tolterodinetablet2 mgoralTeva Canada Limited2015-12-16Not applicableCanada
Teva-tolterodine LAcapsule (extended release)2 mgoralTeva Canada Limited2015-12-16Not applicableCanada
Teva-tolterodine LAcapsule (extended release)4 mgoralTeva Canada Limited2015-12-16Not applicableCanada
Tolterodine Tartratetablet, film coated1 mg/1oralTeva Pharmaceuticals USA Inc2012-05-11Not applicableUs
Tolterodine Tartratecapsule, extended release4 mg/1oralTeva Pharmaceuticals USA Inc2014-01-02Not applicableUs
Tolterodine Tartratecapsule, extended release2 mg/1oralTeva Pharmaceuticals USA Inc2014-01-02Not applicableUs
Tolterodine Tartratetablet, film coated1 mg/1oralGreenstone LLC2014-01-21Not applicableUs
Tolterodine Tartratetablet, film coated2 mg/1oralTeva Pharmaceuticals USA Inc2012-05-11Not applicableUs
Tolterodine Tartratetablet, film coated2 mg/1oralGreenstone LLC2014-01-21Not applicableUs
Tolterodine Tartrate Extended Releasecapsule, extended release2 mg/1oralGreenstone LLC2000-02-22Not applicableUs
Tolterodine Tartrate Extended Releasecapsule, extended release4 mg/1oralGreenstone LLC2000-02-22Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tolterodinetablet1 mgoralApotex Inc2016-03-03Not applicableCanada
Apo-tolterodinetablet2 mgoralApotex Inc2016-03-03Not applicableCanada
Tolterodine Tartratecapsule, extended release4 mg/1oralTorrent Pharmaceuticals Limited2015-08-11Not applicableUs
Tolterodine Tartratetablet, film coated1 mg/1oralTeva Pharmaceuticals USA Inc2015-11-01Not applicableUs
Tolterodine Tartratecapsule, extended release4 mg/1oralMylan Institutional Inc.2014-01-29Not applicableUs
Tolterodine Tartratetablet, film coated1 mg/1oralMylan Pharmaceuticals Inc.2012-11-28Not applicableUs
Tolterodine Tartratetablet, film coated1 mg/1oralMacleods Pharmaceuticals Limited2015-10-08Not applicableUs
Tolterodine Tartratetablet, film coated2 mg/1oralTeva Pharmaceuticals USA Inc2015-11-01Not applicableUs
Tolterodine Tartratetablet, film coated2 mg/1oralMylan Institutional Inc.2013-03-26Not applicableUs
Tolterodine Tartratetablet, film coated2 mg/1oralMylan Pharmaceuticals Inc.2012-11-28Not applicableUs
Tolterodine Tartratetablet, film coated2 mg/1oralMacleods Pharmaceuticals Limited2015-10-08Not applicableUs
Tolterodine Tartratecapsule, extended release2 mg/1oralMylan Pharmaceuticals Inc.2014-01-06Not applicableUs
Tolterodine Tartratetablet, film coated1 mg/1oralApotex Corp.2012-09-25Not applicableUs
Tolterodine Tartratecapsule, extended release2 mg/1oralTorrent Pharmaceuticals Limited2015-08-11Not applicableUs
Tolterodine Tartratecapsule, extended release2 mg/1oralMylan Institutional Inc.2014-01-28Not applicableUs
Tolterodine Tartratecapsule, extended release4 mg/1oralMylan Pharmaceuticals Inc.2014-01-06Not applicableUs
Tolterodine Tartratetablet, film coated2 mg/1oralApotex Corp.2012-09-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DetrusitolNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tolterodine Tartrate
Thumb
  • InChI Key: TWHNMSJGYKMTRB-KXYUELECSA-N
  • Monoisotopic Mass: 475.257002543
  • Average Mass: 475.5745
DBSALT000467
Categories
UNIIWHE7A56U7K
CAS number124937-51-5
WeightAverage: 325.4876
Monoisotopic: 325.240564619
Chemical FormulaC22H31NO
InChI KeyInChIKey=OOGJQPCLVADCPB-HXUWFJFHSA-N
InChI
InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1
IUPAC Name
2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
SMILES
CC(C)N(CC[[email protected]](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • P-cresol
  • Aralkylamine
  • Toluene
  • Phenol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
PharmacodynamicsTolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabolite exhibit a high specificity for muscarinic receptors, since both show negligible activity or affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels. Tolterodine has a pronounced effect on bladder function. The main effects of tolterodine are an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure, consistent with an antimuscarinic action on the lower urinary tract.
Mechanism of actionBoth tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 113 ± 26.7 L
Protein bindingApproximately 96.3%.
Metabolism
SubstrateEnzymesProduct
Tolterodine
N-Dealkylated tolterodineDetails
Tolterodine
5-Hydroxymethyl tolterodineDetails
N-Dealkylated tolterodine
Not Available
N-Dealkylated 5-hydroxymethyl tolterodineDetails
5-Hydroxymethyl tolterodine
Not Available
N-Dealkylated 5-hydroxymethyl tolterodineDetails
5-Hydroxymethyl tolterodine
Not Available
5-Carboxylic acid tolterodineDetails
Route of eliminationFollowing administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days.
Half life1.9-3.7 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.958
Blood Brain Barrier+0.9194
Caco-2 permeable+0.8286
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.6727
P-glycoprotein inhibitor IINon-inhibitor0.8305
Renal organic cation transporterInhibitor0.6904
CYP450 2C9 substrateNon-substrate0.6235
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.8139
CYP450 2C9 inhibitorNon-inhibitor0.6965
CYP450 2D6 inhibitorInhibitor0.7456
CYP450 2C19 inhibitorNon-inhibitor0.5853
CYP450 3A4 inhibitorNon-inhibitor0.8575
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5259
Ames testNon AMES toxic0.6658
CarcinogenicityNon-carcinogens0.7967
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.5503 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8014
hERG inhibition (predictor II)Inhibitor0.6875
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg
Tabletoral2 mg
Tablet, film coatedoral1 mg/1
Tablet, film coatedoral2 mg/1
Capsule (extended release)oral2 mg
Capsule (extended release)oral4 mg
Capsule, extended releaseoral2 mg/1
Capsule, extended releaseoral4 mg/1
Prices
Unit descriptionCostUnit
Detrol LA 2 mg 24 Hour Capsule5.01USD capsule
Detrol LA 4 mg 24 Hour Capsule4.84USD capsule
Detrol la 4 mg capsule4.82USD capsule
Detrol la 2 mg capsule4.81USD capsule
Detrol 2 mg tablet2.85USD tablet
Detrol 1 mg tablet2.77USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1340223 No1998-12-152015-12-15Canada
CA2311755 No2010-03-232019-08-26Canada
US5382600 No1995-03-252012-03-25Us
US6630162 Yes2000-05-112020-05-11Us
US6770295 Yes2000-02-262020-02-26Us
US6911217 Yes2000-05-112020-05-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP5.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00534 mg/mLALOGPS
logP5.39ALOGPS
logP5.12ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.28ChemAxon
pKa (Strongest Basic)11.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity103.96 m3·mol-1ChemAxon
Polarizability39.27 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yatendra Kumar, “PROCESS FOR THE PREPARATION OF TOLTERODINE.” U.S. Patent US20040249211, issued December 09, 2004.

US20040249211
General ReferencesNot Available
External Links
ATC CodesG04BD07
AHFS Codes
  • 86:12.00
PDB EntriesNot Available
FDA labelDownload (94.9 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with 1,10-Phenanthroline.
AbirateroneThe metabolism of Tolterodine can be decreased when combined with Abiraterone.
AclidiniumAclidinium may increase the anticholinergic activities of Tolterodine.
AclidiniumThe risk or severity of adverse effects can be increased when Tolterodine is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Tolterodine is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tolterodine is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Ambenonium.
AmiodaroneTolterodine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Tolterodine can be decreased when combined with Amiodarone.
AnagrelideTolterodine may increase the QTc-prolonging activities of Anagrelide.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Tolterodine.
AprepitantThe serum concentration of Tolterodine can be increased when it is combined with Aprepitant.
ArmodafinilThe metabolism of Tolterodine can be decreased when combined with Armodafinil.
Arsenic trioxideTolterodine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherTolterodine may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Tolterodine can be decreased when combined with Artemether.
AsenapineTolterodine may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe serum concentration of Tolterodine can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Tolterodine can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tolterodine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Tolterodine.
AzithromycinTolterodine may increase the QTc-prolonging activities of Azithromycin.
BedaquilineTolterodine may increase the QTc-prolonging activities of Bedaquiline.
BenactyzineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tolterodine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tolterodine.
BetaxololThe metabolism of Tolterodine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Tolterodine can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Tolterodine is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Tolterodine.
BoceprevirThe serum concentration of Tolterodine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Tolterodine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Tolterodine can be decreased when it is combined with Bosentan.
Botulinum Toxin Type ATolterodine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BTolterodine may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Buprenorphine.
BupropionThe metabolism of Tolterodine can be decreased when combined with Bupropion.
ButorphanolThe risk or severity of adverse effects can be increased when Tolterodine is combined with Butorphanol.
CapecitabineThe metabolism of Tolterodine can be decreased when combined with Capecitabine.
CarbamazepineThe metabolism of Tolterodine can be increased when combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Tolterodine is combined with Carfentanil.
CelecoxibThe metabolism of Tolterodine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Tolterodine can be increased when it is combined with Ceritinib.
CeritinibTolterodine may increase the QTc-prolonging activities of Ceritinib.
ChloramphenicolThe metabolism of Tolterodine can be decreased when combined with Chloramphenicol.
ChloroquineTolterodine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Tolterodine can be decreased when combined with Chloroquine.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Tolterodine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Chlorphenoxamine.
ChlorpromazineTolterodine may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe metabolism of Tolterodine can be decreased when combined with Chlorpromazine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Tolterodine.
CholecalciferolThe metabolism of Tolterodine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Tolterodine can be decreased when combined with Cimetidine.
CimetropiumTolterodine may increase the anticholinergic activities of Cimetropium.
CinacalcetThe metabolism of Tolterodine can be decreased when combined with Cinacalcet.
CiprofloxacinTolterodine may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideTolterodine may increase the QTc-prolonging activities of Cisapride.
CitalopramTolterodine may increase the QTc-prolonging activities of Citalopram.
CitalopramThe metabolism of Tolterodine can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Tolterodine can be increased when it is combined with Clarithromycin.
ClarithromycinTolterodine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Tolterodine can be decreased when combined with Clemastine.
ClobazamThe metabolism of Tolterodine can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Tolterodine can be decreased when combined with Clomipramine.
ClotrimazoleThe metabolism of Tolterodine can be decreased when combined with Clotrimazole.
ClozapineTolterodine may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Tolterodine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Tolterodine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Tolterodine can be decreased when combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Codeine.
ConivaptanThe serum concentration of Tolterodine can be increased when it is combined with Conivaptan.
CoumaphosThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Coumaphos.
CrizotinibTolterodine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Tolterodine can be decreased when combined with Crizotinib.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tolterodine.
CyclosporineThe metabolism of Tolterodine can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Tolterodine can be decreased when it is combined with Dabrafenib.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tolterodine.
DarunavirThe serum concentration of Tolterodine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Tolterodine can be increased when it is combined with Dasatinib.
DecamethoniumThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Decamethonium.
DeferasiroxThe serum concentration of Tolterodine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Tolterodine can be decreased when combined with Delavirdine.
DemecariumThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Demecarium.
DesipramineThe metabolism of Tolterodine can be decreased when combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tolterodine.
DexamethasoneThe serum concentration of Tolterodine can be decreased when it is combined with Dexamethasone.
DexetimideThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tolterodine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Tolterodine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydromorphine.
DiltiazemThe metabolism of Tolterodine can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Tolterodine can be decreased when combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Tolterodine is combined with Diphenoxylate.
DisopyramideTolterodine may increase the QTc-prolonging activities of Disopyramide.
DofetilideTolterodine may increase the QTc-prolonging activities of Dofetilide.
DolasetronTolterodine may increase the QTc-prolonging activities of Dolasetron.
DomperidoneTolterodine may increase the QTc-prolonging activities of Domperidone.
DonepezilThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Donepezil.
DoxycyclineThe metabolism of Tolterodine can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when Tolterodine is combined with DPDPE.
DronabinolTolterodine may increase the tachycardic activities of Dronabinol.
DronedaroneThe metabolism of Tolterodine can be decreased when combined with Dronedarone.
DronedaroneTolterodine may increase the QTc-prolonging activities of Dronedarone.
DroperidolTolterodine may increase the QTc-prolonging activities of Droperidol.
DuloxetineThe metabolism of Tolterodine can be decreased when combined with Duloxetine.
EchothiophateThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Edrophonium.
EfavirenzThe serum concentration of Tolterodine can be decreased when it is combined with Efavirenz.
EliglustatTolterodine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Tolterodine can be decreased when combined with Eliglustat.
EluxadolineTolterodine may increase the constipating activities of Eluxadoline.
EnzalutamideThe serum concentration of Tolterodine can be decreased when it is combined with Enzalutamide.
ErythromycinTolterodine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Tolterodine can be decreased when combined with Erythromycin.
EscitalopramTolterodine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Tolterodine can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Tolterodine can be decreased when combined with Esomeprazole.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Tolterodine.
EthylmorphineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Etorphine.
EtravirineThe serum concentration of Tolterodine can be decreased when it is combined with Etravirine.
FentanylThe risk or severity of adverse effects can be increased when Tolterodine is combined with Fentanyl.
FenthionThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Fesoterodine.
FlecainideTolterodine may increase the QTc-prolonging activities of Flecainide.
FloxuridineThe metabolism of Tolterodine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Tolterodine can be decreased when combined with Fluconazole.
FluorouracilThe metabolism of Tolterodine can be decreased when combined with Fluorouracil.
FluoxetineTolterodine may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe metabolism of Tolterodine can be decreased when combined with Fluoxetine.
FlupentixolTolterodine may increase the QTc-prolonging activities of Flupentixol.
FluvastatinThe metabolism of Tolterodine can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Tolterodine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Tolterodine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Tolterodine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Tolterodine can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Tolterodine can be increased when it is combined with Fusidic Acid.
Gadobenic acidTolterodine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Tolterodine.
GemfibrozilThe metabolism of Tolterodine can be decreased when combined with Gemfibrozil.
GemifloxacinTolterodine may increase the QTc-prolonging activities of Gemifloxacin.
Ginkgo bilobaThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Tolterodine is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Tolterodine.
GlycopyrroniumTolterodine may increase the anticholinergic activities of Glycopyrronium.
GoserelinTolterodine may increase the QTc-prolonging activities of Goserelin.
GranisetronTolterodine may increase the QTc-prolonging activities of Granisetron.
HaloperidolTolterodine may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe metabolism of Tolterodine can be decreased when combined with Haloperidol.
HeroinThe risk or severity of adverse effects can be increased when Tolterodine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tolterodine.
HydrocodoneThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tolterodine.
HydromorphoneThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tolterodine.
IbutilideTolterodine may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Tolterodine can be increased when it is combined with Idelalisib.
IloperidoneTolterodine may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Tolterodine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Tolterodine can be decreased when combined with Imipramine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Tolterodine.
IndinavirThe metabolism of Tolterodine can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tolterodine.
IrbesartanThe metabolism of Tolterodine can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Tolterodine can be decreased when combined with Isavuconazonium.
IsoflurophateThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Isoflurophate.
IsoniazidThe metabolism of Tolterodine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Tolterodine can be decreased when combined with Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Tolterodine.
ItraconazoleThe serum concentration of Tolterodine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Tolterodine can be increased when it is combined with Ivacaftor.
KetobemidoneThe risk or severity of adverse effects can be increased when Tolterodine is combined with Ketobemidone.
KetoconazoleThe metabolism of Tolterodine can be decreased when combined with Ketoconazole.
LeflunomideThe metabolism of Tolterodine can be decreased when combined with Leflunomide.
LenvatinibTolterodine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideTolterodine may increase the QTc-prolonging activities of Leuprolide.
LevofloxacinTolterodine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tolterodine is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Tolterodine is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Tolterodine is combined with Lofentanil.
LopinavirThe serum concentration of Tolterodine can be increased when it is combined with Lopinavir.
LopinavirTolterodine may increase the QTc-prolonging activities of Lopinavir.
LorcaserinThe metabolism of Tolterodine can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Tolterodine can be decreased when combined with Losartan.
LovastatinThe metabolism of Tolterodine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Tolterodine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Tolterodine can be decreased when it is combined with Lumacaftor.
LumefantrineTolterodine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Tolterodine can be decreased when combined with Lumefantrine.
MalathionThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tolterodine.
MefloquineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Tolterodine is combined with Methadone.
MethadoneThe metabolism of Tolterodine can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tolterodine is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Tolterodine.
MethotrimeprazineThe metabolism of Tolterodine can be decreased when combined with Methotrimeprazine.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Tolterodine.
MetixeneThe risk or severity of adverse effects can be increased when Tolterodine is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Tolterodine.
MetoprololThe metabolism of Tolterodine can be decreased when combined with Metoprolol.
MianserinMianserin may increase the anticholinergic activities of Tolterodine.
MifepristoneThe metabolism of Tolterodine can be decreased when combined with Mifepristone.
MifepristoneTolterodine may increase the QTc-prolonging activities of Mifepristone.
MinaprineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Tolterodine is combined with Mirabegron.
MirabegronThe metabolism of Tolterodine can be decreased when combined with Mirabegron.
MitotaneThe serum concentration of Tolterodine can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Tolterodine can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Tolterodine can be decreased when it is combined with Modafinil.
MorphineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Morphine.
MoxifloxacinTolterodine may increase the QTc-prolonging activities of Moxifloxacin.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Tolterodine is combined with N-butylscopolammonium bromide.
NabiloneTolterodine may increase the tachycardic activities of Nabilone.
NafcillinThe serum concentration of Tolterodine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Nalbuphine.
NefazodoneThe serum concentration of Tolterodine can be increased when it is combined with Nefazodone.
NelfinavirThe metabolism of Tolterodine can be decreased when combined with Nelfinavir.
NeostigmineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Neostigmine.
NetupitantThe serum concentration of Tolterodine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Tolterodine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Tolterodine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Tolterodine can be decreased when combined with Nilotinib.
NilotinibTolterodine may increase the QTc-prolonging activities of Nilotinib.
NormethadoneThe risk or severity of adverse effects can be increased when Tolterodine is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Tolterodine is combined with NVA237.
OfloxacinTolterodine may increase the QTc-prolonging activities of Ofloxacin.
OlaparibThe metabolism of Tolterodine can be decreased when combined with Olaparib.
OmeprazoleThe metabolism of Tolterodine can be decreased when combined with Omeprazole.
OndansetronTolterodine may increase the QTc-prolonging activities of Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Tolterodine is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Orphenadrine.
OsimertinibThe serum concentration of Tolterodine can be increased when it is combined with Osimertinib.
OxybutyninThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tolterodine.
PalbociclibThe serum concentration of Tolterodine can be increased when it is combined with Palbociclib.
PaliperidoneTolterodine may increase the QTc-prolonging activities of Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pancuronium.
PanobinostatTolterodine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Tolterodine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Tolterodine can be decreased when combined with Pantoprazole.
ParoxetineThe metabolism of Tolterodine can be decreased when combined with Paroxetine.
PazopanibTolterodine may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Tolterodine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineTolterodine may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pentazocine.
PentobarbitalThe metabolism of Tolterodine can be increased when combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pentolinium.
PerflutrenTolterodine may increase the QTc-prolonging activities of Perflutren.
PethidineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pethidine.
PhenobarbitalThe metabolism of Tolterodine can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Tolterodine can be increased when combined with Phenytoin.
PhysostigmineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Physostigmine.
PimozideTolterodine may increase the QTc-prolonging activities of Pimozide.
PipecuroniumThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tolterodine.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Tolterodine.
PosaconazoleThe serum concentration of Tolterodine can be increased when it is combined with Posaconazole.
Potassium ChlorideTolterodine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Tolterodine.
PrimaquineTolterodine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Tolterodine can be increased when combined with Primidone.
ProcainamideTolterodine may increase the QTc-prolonging activities of Procainamide.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tolterodine.
PromazineTolterodine may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Tolterodine can be decreased when combined with Promazine.
PropafenoneTolterodine may increase the QTc-prolonging activities of Propafenone.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Tolterodine.
PyridostigmineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Pyridostigmine.
PyrimethamineThe metabolism of Tolterodine can be decreased when combined with Pyrimethamine.
QuetiapineTolterodine may increase the QTc-prolonging activities of Quetiapine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Tolterodine.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Tolterodine.
QuinineTolterodine may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Tolterodine can be decreased when combined with Quinine.
RamosetronTolterodine may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Tolterodine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Tolterodine is combined with Remifentanil.
RifabutinThe metabolism of Tolterodine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Tolterodine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Tolterodine can be increased when combined with Rifapentine.
RitonavirThe serum concentration of Tolterodine can be increased when it is combined with Ritonavir.
RivastigmineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Rivastigmine.
RolapitantThe metabolism of Tolterodine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Tolterodine can be decreased when combined with Ropinirole.
SaquinavirThe serum concentration of Tolterodine can be increased when it is combined with Saquinavir.
SaquinavirTolterodine may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tolterodine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Tolterodine is combined with Scopolamine butylbromide.
SecobarbitalThe metabolism of Tolterodine can be increased when combined with Secobarbital.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Tolterodine.
SertralineThe metabolism of Tolterodine can be decreased when combined with Sertraline.
SildenafilThe metabolism of Tolterodine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Tolterodine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Tolterodine can be increased when it is combined with Simeprevir.
SolifenacinThe risk or severity of adverse effects can be increased when Tolterodine is combined with Solifenacin.
SorafenibThe metabolism of Tolterodine can be decreased when combined with Sorafenib.
SotalolTolterodine may increase the QTc-prolonging activities of Sotalol.
St. John's WortThe serum concentration of Tolterodine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Tolterodine can be increased when it is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Tolterodine is combined with Sufentanil.
SulfadiazineThe metabolism of Tolterodine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Tolterodine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleTolterodine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Tolterodine can be decreased when combined with Sulfisoxazole.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tolterodine.
TacrineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Tolterodine is combined with Tapentadol.
TelaprevirThe serum concentration of Tolterodine can be increased when it is combined with Telaprevir.
TelavancinTolterodine may increase the QTc-prolonging activities of Telavancin.
TelithromycinThe serum concentration of Tolterodine can be increased when it is combined with Telithromycin.
TelithromycinTolterodine may increase the QTc-prolonging activities of Telithromycin.
TerbinafineThe metabolism of Tolterodine can be decreased when combined with Terbinafine.
TetrabenazineTolterodine may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineTolterodine may increase the QTc-prolonging activities of Thioridazine.
ThioridazineThe metabolism of Tolterodine can be decreased when combined with Thioridazine.
TicagrelorThe metabolism of Tolterodine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Tolterodine can be decreased when combined with Ticlopidine.
TiotropiumTolterodine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Tolterodine.
TipranavirThe metabolism of Tolterodine can be decreased when combined with Tipranavir.
TocilizumabThe serum concentration of Tolterodine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Tolterodine can be decreased when combined with Tolbutamide.
TopiramateThe risk or severity of adverse effects can be increased when Tolterodine is combined with Topiramate.
TopiramateThe metabolism of Tolterodine can be decreased when combined with Topiramate.
ToremifeneTolterodine may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tolterodine is combined with Tramadol.
TranylcypromineThe metabolism of Tolterodine can be decreased when combined with Tranylcypromine.
TrichlorfonThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Tolterodine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tolterodine.
TrimethaphanThe risk or severity of adverse effects can be increased when Tolterodine is combined with Trimethaphan.
TrimethoprimThe metabolism of Tolterodine can be decreased when combined with Trimethoprim.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tolterodine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Tolterodine.
TubocurarineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Tolterodine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Tolterodine is combined with Umeclidinium.
Valproic AcidThe metabolism of Tolterodine can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Tolterodine can be decreased when combined with Valsartan.
VandetanibTolterodine may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe risk or severity of adverse effects can be increased when Tolterodine is combined with Vecuronium.
VemurafenibTolterodine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Tolterodine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Tolterodine can be decreased when combined with Verapamil.
VinblastineThe serum concentration of Tolterodine can be increased when it is combined with Vinblastine.
VoriconazoleThe metabolism of Tolterodine can be decreased when combined with Voriconazole.
WarfarinTolterodine may increase the anticoagulant activities of Warfarin.
ZafirlukastThe metabolism of Tolterodine can be decreased when combined with Zafirlukast.
ZiprasidoneThe metabolism of Tolterodine can be decreased when combined with Ziprasidone.
ZiprasidoneTolterodine may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolTolterodine may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Schneider T, Fetscher C, Krege S, Michel MC: Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. Epub 2004 Feb 9. [PubMed:14769832 ]
  3. McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS: Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. Eur J Pharmacol. 2009 Mar 1;605(1-3):145-52. doi: 10.1016/j.ejphar.2008.12.043. Epub 2009 Jan 10. [PubMed:19168050 ]
  4. Sellers DJ, Yamanishi T, Chapple CR, Couldwell C, Yasuda K, Chess-Williams R: M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro. J Auton Pharmacol. 2000 Jun;20(3):171-6. [PubMed:11193006 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nelson CP, Nahorski SR, Challiss RA: Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther. 2006 Jan;316(1):279-88. Epub 2005 Sep 27. [PubMed:16188951 ]
  2. Schneider T, Fetscher C, Krege S, Michel MC: Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. Epub 2004 Feb 9. [PubMed:14769832 ]
  3. McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS: Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. Eur J Pharmacol. 2009 Mar 1;605(1-3):145-52. doi: 10.1016/j.ejphar.2008.12.043. Epub 2009 Jan 10. [PubMed:19168050 ]
  4. Sellers DJ, Yamanishi T, Chapple CR, Couldwell C, Yasuda K, Chess-Williams R: M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro. J Auton Pharmacol. 2000 Jun;20(3):171-6. [PubMed:11193006 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9. [PubMed:16406943 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Schneider T, Fetscher C, Krege S, Michel MC: Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. Epub 2004 Feb 9. [PubMed:14769832 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9. [PubMed:16406943 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Postlind H, DanielsonA, Lindgren A, Andersson SH: Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93. [PubMed:9531513 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 03:38